You missed this – Subscribe & Avoid FOMO!
Cure for Cancer: Myth Or Reality?


Wed 3 May 2017, 6:30pm–8:00pm

Where: AMRF Lecture Theatre, University of Auckland, 85 Park Road, Grafton, Auckland

Restrictions: All Ages

Ticket Information:

  • General Admission (free): $0.00
  • Additional fees may apply


Cancer Society Auckland Northland is proud to invite you to the main event for this year’s Cancer Research Week, a public lecture by world-renowned researcher Professor David (Herbie) Newell.

Register now to reserve your free ticket.

People are now being successfully treated for cancer at ever increasing rates. In the late 70’s the five-year survival rate for people diagnosed with cancer was below 25% and in 2017 it over 50%.

Professor Newell will present on the cancer burden, incidence and trends in research and treatment, recent insights into the molecular events underlying cancer and the development of new “targeted” cancer treatments. He will also discuss how our current understanding of cancer and the new generation of treatments has allowed us to develop a “holistic” view of how the cancer problem can be managed and the future challenges for cancer research.

Professor Newell is Emeritus Professor of Cancer Therapeutics at Newcastle University, England, UK. He was Director of Translational Research at Cancer Research UK from 2006 to 2009, and interim Executive Director of Clinical and Translational Research in 2007/8.

He was the founding Scientific Director of the Northern Institute for Cancer Research at Newcastle University and is Past-Chairman of the British Association for Cancer Research and of the Laboratory Research Division of the European Organisation for Research and Treatment of Cancer.

Professor Newell has been involved in research on a number of commercially available cancer drugs. Professor Newell was involved in the development of the registered cytotoxic agents carboplatin (Paraplatin) and ralitrexed (Tomudex).

Professor Newell was the lead pharmacologist on the team that discovered the first-in-class PARP inhibitor rucaparib (Rubraca), for which the team were awarded the inaugural Cancer Research UK Translational Research Team prize. Rucaparib was given “Breakthrough Therapy” status by the US FDA in April 2015 for the treatment of hereditary ovarian cancer.

We invite anyone with an interest in cancer and its treatment to this event.

Restaurants to book near Cure for Cancer: Myth Or Reality?